CSIMarket.com
Legend Biotech Corporation (NASDAQ: LEGN), a renowned global leader in cell therapy, is making significant strides in the development of CAR-T cell therapy for patients with multiple myeloma. The company has recently participated in the Jefferies Global Healthcare Conference and announced the presentation of new data from the CARTITUDE clinical development program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Associations (EHA) Hybrid Congress. Additionally, Legend Biotech has received approval from the European Commission for the second-line treatment of relapsed and refractory multiple myeloma patients with CARVYKTI (ciltacabtagene autoleucel).
Excerpt 1: Jefferies Global Healthcare Conference Participation
Legend Biotech’s Chief LEGN Dr. Ying Huang, will be participating in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 6, 2024. The live webcast of the event will be accessible to investors and other interested parties through the Investor Relations section of the company’s website.
Excerpt 2: CAR-T Cell Therapy Highlights at ASCO and EHA
The latest results from the CARTITUDE clinical development program, evaluating CARVYKTI for multiple myeloma patients, will be presented at the 2024 ASCO Annual Meeting and the 2024 EHA Hybrid Congress. This data is expected to shed light on the efficacy and safety of CARVYKTI in treating the disease.
Excerpt 3: European Commission’s Approval of CARVYKTI
Legend Biotech received approval from the European Commission for the use of CARVYKTI in adult patients with relapsed and refractory multiple myeloma, who have received prior therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and demonstrated disease progression.
Conclusion:
Legend Biotech is at the forefront of the CAR-T cell therapy revolution, particularly in the field of multiple myeloma treatment. Through their participation in the Jefferies Global Healthcare Conference, the company aims to emphasize their leadership in this innovative therapy. Furthermore, the presentation of new data from the CARTITUDE clinical development program at the upcoming ASCO and EHA conferences highlights Legend Biotech’s commitment to advancing the treatment options for multiple myeloma patients. The European Commission’s approval of CARVYKTI provides a significant boost to the company’s efforts in addressing the needs of relapsed and refractory multiple myeloma patients.
Comments